Cargando…
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494633/ https://www.ncbi.nlm.nih.gov/pubmed/23170267 http://dx.doi.org/10.4161/onci.20591 |
| Sumario: | This commentary provides the authors’ perspective on the article “Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial,” which has recently been published in The Lancet Oncology. |
|---|